Adamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal

Adamas Pharmaceuticals (Nasdaq:ADMS) announced that results of its Phase 2 proof-of-concept clinical trial of ADS-5102 (amantadine) extended release capsules in multiple sclerosis (MS) patients with walking impairment were published online in Multiple Sclerosis Journal.

As quoted in the press release:

“In this proof-of-concept study, a greater proportion of ADS-5102 patients had at least a 20 percent improvement in walking speed compared with the placebo group,” stated Jeffrey A. Cohen, M.D., Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, and a paid consultant for Adamas.

Click here to read the full press release.